All In MedTech

FDA Clearance Tracker · P040045-S041

VISTAKON (SENOFILCON A) BRAND CONTACT LENSES

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 16, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 16, 2014

Approved

Time to decision

59 days

Received Nov 18, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P040045-S041
Device name
VISTAKON (SENOFILCON A) BRAND CONTACT LENSES
Applicant location
Jacksonville, FL
Received
Nov 18, 2013
Decided
Jan 16, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P040045

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A CHANGE IN THE VISCOSITY SPECIFICATION FROM 120-170 CPS TO100-170 CPS FOR THE REACTIVE MONOMER MIX.

Source documents

Other decisions for Vistakon, Division of Johnson & Johnson Vision Car

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.